Table 3.

Plasma protein changes from baseline to C2D1

ProteinsNo. of patientsLODBaseline median (range)C2D1 median (range)Percent change from baselineP valuea
VEGF-A (pg/mL)b1429 pg/mL100.5 (<LOD – 4,678)8.3 (<LOD – 75.5)−92.7<0.001
sVEGFR2 (pg/mL)1494.6 pg/mL8,724 (5,359–14,730)9,128 (4,670–14,780)5.1<0.001
ANG2 (pg/mL)1428.29 pg/mL2,922 (700–31,745)2,340 (833–9,461)−18.1<0.001
sTIE2 (ng/mL)14214 pg/mL25.2 (14.1–120)22.5 (12.3–68.7)−10.5<0.001
IL6 (pg/mL)1490.06 pg/mL1.29 (0.21–34.8)1.27 (0.12–121)−14.10.055
IL8 (pg/mL)1490.04 pg/mL10.2 (0.82–215.7)9.3 (2.0–97.5)−11.00.021
CA9 (pg/mL)1482.28 pg/mL74.6 (14.5–1,700)98.2 (16.6–1,001)31.0<0.001

Abbreviations: LOD, limit of detection.

  • aWilcoxon signed-rank test.

  • bVEGF-A levels were below the lower limit of detection in four baseline samples (one in AT and three in ATX) and in 85 C2D1 samples (46 in AT and 39 in ATX).